Association between risperidone treatment and cerebrovascular adverse events in elderly patients with dementia [8]

Journal of the American Geriatrics Society

Volumn 53, Issue 8, 2005, Pages 1446-1448

  Formiga, Francesc ^a   Fort, Isabel ^b   Pérez Castejón, Juan Manel ^c   Ruiz, Domingo ^d   Duaso, Enric ^e   Riu, Sebastia ^f  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Centre Sociosanitari El Carme   (Spain)

^c Clinica Barceloneta   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL MÚTUA DE TERRASSA   (Spain)

^f Psychogeriatric Unit   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HALOPERIDOL; LEVOMEPROMAZINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; NEUROLEPTIC AGENT;

AGED; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; LETTER; MAJOR CLINICAL STUDY; MALE; STROKE; TRANSIENT ISCHEMIC ATTACK; CHEMICALLY INDUCED DISORDER; NOTE;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CEREBROVASCULAR DISORDERS; DEMENTIA; FEMALE; HUMANS; MALE; RISPERIDONE;

EID: 25144496010     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2005.53433_8.x     Document Type: Letter

References (10)

1. Finkel S. Pharmacology of antipsychotics in the elderly: A focus on atypicals. J Am Geriatr Soc 2004;52:S258-S265.
2. Katz IR. Optimizing atypical antipsychotic treatment strategies in the elderly. J Am Geriatr Soc 2004;52:S272-S277.
3. Katz IR, Jeste DV, Mintzer JE et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60: 107-115.
4. Brodaty H, Ames D, Snowdon J et al. A randomized placebo-controlled trail of risperidone for the treatment of agression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-143.
5. De Deyn PP, Rabheru K, Rasmussen A et al. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology 1999;22:946-955.
6. Wooltorton E. Risperidone (risperdal). Increased rate of cerebrovascular events in dementia trials. Can Med Assoc J 2002;167:1269-1270.
7. Liperoti R, Gambassi G, Lapane K et al. Cerebrovascular events among elderly patients treated with conventional or atypical antipsychotics [abstract]. J Am Geriatr Soc 2004;52(Suppl 1):9A.
8. de Clerck F, Beetens J, de Chaffoy, et al. R 68 070: Thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. Biochemical profile in vitro. Thromb Haemost 1989;61:35-42.
9. de Clerck F, Xhonneux B, de Chaffoy, et al. Functional expression of the amplification reaction between serotonin and epinephrine on platelets. J Cardiovasc Pharmacol 1988;11(Suppl 1):S1-S5.
10. de Clerck F, Xhonneux B, Leysen J et al. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol 1984;33: 2807-2811.